Aquestive Therapeutics (AQST) Competitors

Aquestive Therapeutics (NASDAQ:AQST) and Adaptive Biotechnologies (NASDAQ:ADPT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk and dividends.

Is AQST or ADPT more profitable?

Adaptive Biotechnologies has a net margin of -74.84% compared to Aquestive Therapeutics' net margin of -100.02%. Aquestive Therapeutics' return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aquestive Therapeutics	-100.02%	N/A	-50.31%
Adaptive Biotechnologies	-74.84%	-62.79%	-24.55%

Which has higher valuation and earnings, AQST or ADPT?

Aquestive Therapeutics has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Aquestive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aquestive Therapeutics	$57.56M	7.25	-$44.14M	-$0.59	-7.12
Adaptive Biotechnologies	$178.96M	9.05	-$159.49M	-$0.96	-11.10

Which has more risk and volatility, AQST or ADPT?

Aquestive Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500.

Do analysts prefer AQST or ADPT?

Aquestive Therapeutics currently has a consensus target price of $10.14, indicating a potential upside of 141.50%. Adaptive Biotechnologies has a consensus target price of $10.57, indicating a potential downside of 0.83%. Given Aquestive Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aquestive Therapeutics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aquestive Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Adaptive Biotechnologies	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Does the media refer more to AQST or ADPT?

In the previous week, Adaptive Biotechnologies had 6 more articles in the media than Aquestive Therapeutics. MarketBeat recorded 9 mentions for Adaptive Biotechnologies and 3 mentions for Aquestive Therapeutics. Adaptive Biotechnologies' average media sentiment score of 0.95 beat Aquestive Therapeutics' score of 0.00 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aquestive Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders believe in AQST or ADPT?

32.5% of Aquestive Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 8.4% of Aquestive Therapeutics shares are held by insiders. Comparatively, 6.4% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Aquestive Therapeutics beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.